Rindi G, Klimstra DS, Abedi-Ardekani B, et al (2018) A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31:1770-1786. https://doi.org/10.1038/s41379-018-0110-y

Article  PubMed  PubMed Central  Google Scholar 

Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, Colao A (2022) Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev Endocrinol Metab 17:389-403. https://doi.org/10.1080/17446651.2022.2099840

Article  PubMed  Google Scholar 

Asa SL, Asioli S, Bozkurt S, et al (2020) Pituitary neuroendocrine tumors (PitNETs): nomenclature evolution, not clinical revolution. Pituitary 23:322-325. https://doi.org/10.1007/s11102-019-01015-0

Article  PubMed  Google Scholar 

Asa SL, Mete O, Cusimano MD, McCutcheon IE, et al (2021) Pituitary neuroendocrine tumors: a model for neuroendocrine tumor classification. Mod Pathol 34:1634-1650. https://doi.org/10.1038/s41379-021-00820-y

Article  PubMed  Google Scholar 

Uccella S, Finzi G, Sessa F, La Rosa S (2020) On the endless dilemma of neuroendocrine neoplasms of the breast: a journey through concepts and entities. Endocr Pathol 31:321-329. https://doi.org/10.1007/s12022-020-09637-y

Article  PubMed  Google Scholar 

Uccella S (2022) The classification of neuroendocrine neoplasms of the breast and its clinical relevance. Virchows Arch 481:3-12. https://doi.org/10.1007/s00428-021-03223-1

Article  PubMed  Google Scholar 

Rakha E, Tan PH (2022) Head to head: do neuroendocrine tumours in the breast truly exist? Histopathology 81:2-14. https://doi.org/10.1111/his.14627

Article  PubMed  Google Scholar 

Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, Ezzat S, de Herder WW, Klimstra DS, Papotti M, Asa SL (2022) Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. Endocr Pathol 33:115-154. https://doi.org/10.1007/s12022-022-09708-2

Article  PubMed  Google Scholar 

Asa SL, Uccella S, Tischler A (2023) The unique importance of differentiation and function in endocrine neoplasia. Endocr Pathol 34:382-392. https://doi.org/10.1007/s12022-023-09762-4

Article  PubMed  Google Scholar 

Uccella S, La Rosa S, Metovic J, Marchiori D, Scoazec JY, Volante M, Mete O, Papotti M (2021) Genomics of high-grade neuroendocrine neoplasms: well-differentiated neuroendocrine tumor with high-grade features (G3 NET) and neuroendocrine carcinomas (NEC) of various anatomic sites. Endocr Pathol 32:192-210. https://doi.org/10.1007/s12022-020-09660-z

Article  PubMed  Google Scholar 

Volante M, Mete O, Pelosi G, Roden AC, Speel EJM, Uccella S (2021) Molecular pathology of well-differentiated pulmonary and thymic neuroendocrine tumors: what do pathologists need to know? Endocr Pathol 32:154-168. https://doi.org/10.1007/s12022-021-09668-z

Article  PubMed  PubMed Central  Google Scholar 

Asa SL, La Rosa S, Basturk O, Adsay V, Minnetti M, Grossman AB (2021) Molecular pathology of well-differentiated gastro-entero-pancreatic neuroendocrine tumors. Endocr Pathol 32:169-191. https://doi.org/10.1007/s12022-021-09662-5

Article  PubMed  Google Scholar 

Yachida S, Vakiani E, White CM, et al (2012) Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors. Am J Surg Pathol 36:173-84. https://doi.org/10.1097/PAS.0b013e3182417d36

Article  PubMed  PubMed Central  Google Scholar 

Scarpa A, Chang DK, Nones K, et al (2017) Whole-genome landscape of pancreatic neuroendocrine tumours. Nature 543:65-71. https://doi.org/10.1038/nature21063

Article  ADS  PubMed  Google Scholar 

Rekhtman N, Pietanza MC, Hellmann MD, et al (2016) Next-generation sequencing of pulmonary large cell neuroendocrine carcinoma reveals small cell carcinoma-like and non-small cell carcinoma-like subsets. Clin Cancer Res 22:3618-29. https://doi.org/10.1158/1078-0432.CCR-15-2946

Article  PubMed  PubMed Central  Google Scholar 

Pelosi G, Bianchi F, Dama E, Simbolo M, Mafficini A, Sonzogni A, Pilotto S, Harari S, Papotti M, Volante M, Fontanini G, Mastracci L, Albini A, Bria E, Calabrese F, Scarpa A (2018) Most high-grade neuroendocrine tumours of the lung are likely to secondarily develop from pre-existing carcinoids: innovative findings skipping the current pathogenesis paradigm. Virchows Arch 472:567-577. https://doi.org/10.1007/s00428-018-2307-3

Article  PubMed  Google Scholar 

Alcala N, Leblay N, Gabriel AAG, et al (2019) Integrative and comparative genomic analyses identify clinically relevant pulmonary carcinoid groups and unveil the supra-carcinoids. Nat Commun 10:3407. https://doi.org/10.1038/s41467-019-11276-9

Article  ADS  PubMed  PubMed Central  Google Scholar 

Pelosi G, Melocchi V, Dama E, Hofman P, De Luca M, Albini A, Gemelli M, Ricotta R, Papotti M, La Rosa S, Uccella S, Harari S, Sonzogni A, Asiedu MK, Wigle DA, Bianchi F (2024) An in-silico analysis reveals further evidence of an aggressive subset of lung carcinoids sharing molecular features of high-grade neuroendocrine neoplasms. Exp Mol Pathol 135:104882. https://doi.org/10.1016/j.yexmp.2024.104882

Article  PubMed  Google Scholar 

La Rosa S, Uccella S (2021) Classification of neuroendocrine neoplasms: lights and shadows. Rev Endocr Metab Disord 22:527-538. https://doi.org/10.1007/s11154-020-09612-2

Article  PubMed  Google Scholar 

Klimstra D, Kloppel G, La Rosa S, Rindi G (2019) Classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification od Tumours Editorial Board, editors. Digestive System Tumours. Lyon: IARC Press. pp. 16-19

Google Scholar 

La Rosa S (2023) Diagnostic, prognostic, and predictive role of ki67 proliferative index in neuroendocrine and endocrine neoplasms: past, present, and future. Endocr Pathol 34:79-97. https://doi.org/10.1007/s12022-023-09755-3

Article  PubMed  PubMed Central  Google Scholar 

Pelosi G, Travis WD (2021) The Ki-67 antigen in the new 2021 World Health Organization classification of lung neuroendocrine neoplasms. Pathologica 113:377-387. https://doi.org/10.32074/1591-951X-542

Article  PubMed  PubMed Central  Google Scholar 

Sorbye H, Welin S, Langer SW, et al (2013) Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 24:152-160. https://doi.org/10.1093/annonc/mds276

Article  PubMed  Google Scholar 

Vélayoudom-Céphise FL, Duvillard P, Foucan L, et al (2013) Are G3 ENETS neuroendocrine neoplasms heterogeneous? Endocr Relat Cancer 20:649-657. https://doi.org/10.1530/ERC-13-0027

Article  PubMed  Google Scholar 

Basturk O, Yang Z, Tang LH, Hruban RH, Adsay V, McCall CM, Krasinskas AM, Jang KT, Frankel WL, Balci S, Sigel C, Klimstra DS (2015) The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol 39:683-690. https://doi.org/10.1097/PAS.0000000000000408

Article  PubMed  PubMed Central  Google Scholar 

Lloyd RV, Osamura RY, Klöppel G, Rosai J, editors. WHO classification of tumours of endocrine organs. Lyon: IARC; 2017.

Marchiò C, Gatti G, Massa F, Bertero L, Filosso P, Pelosi G, Cassoni P, Volante M, Papotti M (2017) Distinctive pathological and clinical features of lung carcinoids with high proliferation index. Virchows Arch 471:713-720. https://doi.org/10.1007/s00428-017-2177-0

Article  PubMed  PubMed Central  Google Scholar 

Quinn AM, Chaturvedi A, Nonaka D (2017) High-grade neuroendocrine carcinoma of the lung with carcinoid morphology: a study of 12 cases. Am J Surg Pathol 41:263-270. https://doi.org/10.1097/PAS.0000000000000767

Article  PubMed  Google Scholar 

Simbolo M, Barbi S, Fassan M, et al (2019) Gene expression profiling of lung atypical carcinoids and large cell neuroendocrine carcinomas identifies three transcriptomic subtypes with specific genomic alterations. J Thorac Oncol 14:1651-1661. https://doi.org/10.1016/j.jtho.2019.05.003

Article  PubMed  Google Scholar 

Liu AJ, Ueberroth BE, McGarrah PW, Buckner Petty SA, Kendi AT, Starr J, Hobday TJ, Halfdanarson TR, Sonbol MB (2021) Treatment outcomes of well-differentiated high-grade neuroendocrine tumors. Oncologist 26:383-388. https://doi.org/10.1002/onco.13686

Article  PubMed  PubMed Central  Google Scholar 

Ostwal V, Basu S, Bhargava P, Shah M, Parghane RV, Srinivas S, Chaudhari V, Bhandare MS, Shrikhande SV, Ramaswamy A (2021) Capecitabine-temozolomide in advanced grade 2 and grade 3 neuroendocrine neoplasms: benefits of chemotherapy in neuroendocrine neoplasms with significant 18FDG uptake. Neuroendocrinology 111:998-1004. https://doi.org/10.1159/000511987

Article  PubMed  Google Scholar 

van Riet J, van de Werken HJG, Cuppen E, Eskens FALM, Tesselaar M, van Veenendaal LM, Klümpen HJ, Dercksen MW, Valk GD, Lolkema MP, Sleijfer S, Mostert B (2021) The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets. Nat Commun 12:4612. https://doi.org/10.1038/s41467-021-24812-3

Article  ADS  PubMed  PubMed Central  Google Scholar 

Puccini A, Poorman K, Salem ME, et al (2020) Comprehensive genomic profiling of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Clin Cancer Res 26:5943-5951. https://doi.org/10.1158/1078-0432.CCR-20-1804

Article  PubMed  PubMed Central  Google Scholar 

Sun TY, Zhao L, Van Hummelen P, Martin B, Hornbacker K, Lee H, Xia LC, Padda SK, Ji HP, Kunz P (2022) Exploratory genomic analysis of high-grade neuroendocrine neoplasms across diverse primary sites. Endocr Relat Cancer 29:665-679. https://doi.org/10.1530/ERC-22-0015

Article  PubMed  PubMed Central  Google Scholar 

Yachida S, Totoki Y, Noë M, et (2022) Comprehensive genomic profiling of neuroendocrine carcinomas of the gastrointestinal system. Cancer Discov 12:692-711.